Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6019571 | 0.85 | TACR1 (0.62) | TACR1TACR3CYP3A4 | |
| SCHEMBL5966330 | 0.81 | TACR1 (0.63) | TACR1TACR3CYP3A4 | |
| SCHEMBL6664695 | 0.78 | TACR1 (0.47) | TACR1TACR3CYP3A4 | |
| SCHEMBL5759750 | 0.76 | TACR1 (0.78) | TACR1TACR3CYP3A4 | |
| SCHEMBL5778839 | 0.74 | TACR1 (0.65) | TACR1TACR3 | |
| SCHEMBL7760176 | 0.74 | TACR1 (0.78) | TACR1TACR3CYP3A4 | |
| SCHEMBL6016366 | 0.73 | TACR1 (0.51) | TACR1TACR3CYP3A4 | |
| SCHEMBL6521395 | 0.73 | TACR1 (0.48) | TACR1TACR3 | |
| SCHEMBL6521392 | 0.71 | TACR1 (0.44) | TACR1TACR3CYP3A4 | |
| SCHEMBL6664699 | 0.68 | TACR1 (0.57) | TACR1TACR3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053954-A1 | METHOD OF TREATMENT AND/OR PREVENTION OF BRAIN, SPINAL OR NERVE INJURY | HOFFMANN TORSTEN | 2011-03-03 | — | — | US | disclosed |
| US-20060247240-A1 | Method of treatment and/or prevention of brain, spinal or nerve injury | HOFFMANN TORSTEN | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053954-A1 | METHOD OF TREATMENT AND/OR PREVENTION OF BRAIN, SPINAL OR NERVE INJURY | NTSR1, NTRK2, NMUR1 | TACR1 14/4885RAF1 392/4885BRAF 838/4885 |
| US-20060247240-A1 | Method of treatment and/or prevention of brain, spinal or nerve injury | NTSR1, NTRK2, NMUR1 | TACR1 10/4885RAF1 394/4885BRAF 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.